Sugemalimab
Sugemalimab Basic information
- Product Name:
- Sugemalimab
- Synonyms:
-
- Sugemalimab
- Research Grade Sugemalimab (DHJ70110)
- Research Grade Sugemalimab
- Sugemalimab (anti-PD-L1)
- CAS:
- 2256084-03-2
- MW:
- 0
- Mol File:
- Mol File
Sugemalimab Chemical Properties
- storage temp.
- Store at -20°C
- form
- Liquid
- color
- Colorless to light yellow
Sugemalimab Usage And Synthesis
Uses
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research[1].
in vivo
Sugemalimab (CS1001) signifcantly inhibits tumor growth in the subcutaneous MC38-hPD-L1 murine colon carcinoma (murine MC38 cells expressing human PD-L1) in human PD-1 knock-in mouse model[2].
Sugemalimab not only enhances the cytotoxic T cell/regulatory T cell ratio, but also significantly upregulates M1 macrophage and down-regulated MDSC (myeloid-derived suppressor cells) population in D-1/PD-L1 dual knock-in mice implanted with MC38-hPD-L1 tumor[2].
References
[1] Dhillon S, et al. Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599. DOI:10.1007/s40265-022-01693-4
[2] Zhang J, et al. The preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation. Cancer Research, 2020, 80(16_Supplement): 3260-3260.
SugemalimabSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com
- Tel
- 4008200310
- marketing@tsbiochem.com